ClinicalTrials.gg
CompletedNCT03810625Updated Aug 7, 2019

Food Effect Study of D-0502 Tablet in Healthy Volunteers

A Phase 1 interventional study of D-0502 in Breast Cancer, sponsored by InventisBio Co., Ltd. Completed at 1 site in United States. Open to female participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-07.

Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2018, 7 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

This is an open label, randomized, balanced, single dose, two-treatment (fed vs. fasting), two-period, two-sequence crossover study of postmenopausal female healthy subjects.

02

Conditions studied

  • Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 14 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be medically documented as healthy and acceptable at physical examination.
  2. Subjects must have a between 18.0 and 32.0 kg/m2 and a body weight of 45 kg or higher.
  3. Subjects must have all laboratory parameters within the normal range or considered not by the principal investigator.
  4. Subjects must have a normal urinalysis, , or results considered not clinically significant by the principal investigator.
  5. Subjects must be female with status defined as meeting at least one of the following criteria:

    1. Have undergone a bilateral oophorectomy any time in life;
    2. Age ≥60 years, or
    3. Age \<60 years but have cessation of regular menses ≥12 months with follicle stimulating hormone (FSH) value >40 milli-international units per milliliter (mIU/mL) and an estradiol value \<40 picograms per milliliter (pg/mL) (140 picomoles per liter [pmol/L]).
  6. Subjects are able to understand the study procedures and risks involved and must provide signed to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any history or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological or psychiatric disorders, as determined by the investigator.
  2. Subjects who have any history or suspicion of kidney stones.
  3. Subjects who are positive for (HIV), , and/or .
  4. Subjects who have used prescription drugs, over-the-counter drugs, or natural health products (including herbal remedies, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 14 days before Day 1 of study medication dosing.
  5. Subjects had undergone major surgery within 3 months prior to Day 1.
  6. Subjects who is participating in a clinical research study involving the administration of an or marketed drug or device, or who received any investigational test article within 5 half-lives or 30 days prior to Day 1 study medication dosing.
  7. Subjects with positive urine drug screen test at screening.
  8. Subjects with any condition that, in the judgment of the investigator, would place him/her at undue risk, or potentially compromise the results or interpretation of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Sequence AB

    D-0502 Dose Patients will get D-0502 single agent once in the fasted state and once in the fed state.

    Drug: D-0502

  • Experimental
    Sequence BA

    D-0502 Dose Patients will get D-0502 single agent once in the fed state and once in the fasted state.

    Drug: D-0502

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic: area under the plasma concentration versus time curve (AUC)

    AUC: area under the plasma concentration versus time curve for D-0502; Unit: nM\*hr

    Time frame: Day 1 through 4, Day 7 through 11

  2. Pharmacokinetic: maximum plasma drug concentration (Cmax)

    Cmax: maximum plasma drug concentration of D-0502; Unit: nM

    Time frame: Day 1 through 4, Day 7 through 11

  3. Pharmacokinetic: Time to reach the Cmax (Tmax)

    Tmax: Time to reach the Cmax of D-0502; Unit: hr

    Time frame: Day 1 through 4, Day 7 through 11

  4. Pharmacokinetic: Apparent terminal half-life (t1/2)

    t1/2: apparent terminal half-life of D-0502; Unit: hr

    Time frame: Day 1 through 4, Day 7 through 11

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Number of treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 2 weeks

07

Study locations

1 site
  • Covance Daytona Beach Clinical Research Unit
    Daytona Beach, Florida 32117, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Nov 2018, 0 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 0 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2018
First posted
Jan 18, 2019
StartActual
Oct 23, 2018
Primary completionActual
Nov 21, 2018
CompletionActual
Apr 17, 2019
Last update
Aug 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03810625
Responsible party
Sponsor
First posted
Jan 18, 2019
Start date
Oct 23, 2018
Primary completion
Nov 21, 2018
Completion
Apr 17, 2019
Last update
Aug 7, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Taragarestrant

Start the discussion